Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.28723PMID 24752335PMCID PMC4117471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

  2014cited by this paper
• Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors

  2014cited by this paper
• Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

  2013cited by this paper
• Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

  2013cited by this paper
• A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.

  2013cited by this paper
• Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

  2013cited by this paper
• The quest to overcome resistance to EGFR-targeted therapies in cancer

  2013cited by this paper
• Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

  2013cited by this paper
• Epidermal growth factor receptor inhibition in lung cancer: status 2012.

  2013cited by this paper
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013influential reference
• Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer

  2013influential reference
• Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

  2013cited by this paper
• Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

  2013influential reference
• High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?

  2013cited by this paper
• Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed

  2013cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

  2013cited by this paper
• Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.

  2013cited by this paper
• Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

  2012cited by this paper
• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

  2012cited by this paper
• Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.

  2012cited by this paper
• ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS

  2012influential reference
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012influential reference
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

  2012influential reference
• When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

  2012cited by this paper
• Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

  2012influential reference
• EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

  2012influential reference
• Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

  2012influential reference
• Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

  2012influential reference
• "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

  2011cited by this paper
• New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

  2011cited by this paper
• Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

  2011cited by this paper
• Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

  2011influential reference
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011influential reference
• Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

  2011influential reference
• Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

  2011cited by this paper
• Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

  2011cited by this paper
• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  2011influential reference
• Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011influential reference
• Drug-induced effects on erlotinib metabolism.

  2011cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

  2010influential reference
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

  2010cited by this paper
• Second‐line treatments after first‐line gefitinib therapy in advanced nonsmall cell lung cancer

  2010cited by this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010influential reference
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

  2009cited by this paper
• Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

  2009cited by this paper
• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

  2009cited by this paper
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

  2008cited by this paper
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

  2008influential reference
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007influential reference
• PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007influential reference
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Effects of Smoking on the Pharmacokinetics of Erlotinib

  2006cited by this paper
• EGFR mutations in small-cell lung cancers in patients who have never smoked.

  2006cited by this paper
• Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

  2006influential reference
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper

• Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis

  2024cites this paper
• Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors

  2024cites this paper
• Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis

  2023cites this paper
• Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition

  2022cites this paper
• Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

  2022cites this paper
• Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid

  2022cites this paper
• Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis.

  2021cites this paper
• Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response

  2021cites this paper
• MET targeting: time for a rematch

  2020cites this paper
• Genomic signatures in pediatric advanced stage Burkitt lymphoma/ leukemia in Chinese population by next generation sequencing

  2020cites this paper
• Genomic signatures in pediatric advanced stage Burkitt lymphoma/leukemia in a Chinese population detected by next generation sequencing

  2020cites this paper
• Effective targeted therapy based on dynamic monitoring of gene mutations in non-small cell lung cancer.

  2019cites this paper
• First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.

  2019cites this paper
• Demonstrated Clinical Utility of Target SelectorTM ctDNA Testing: Liquid Biopsy eGFR Mutation Detection Enabled Targeted Therapy Selection for Three Advanced NSCLC Patients

  2019cites this paper
• Next generation sequencing guided molecular diagnostic tests in non-small-cell lung cancer

  2019cites this paper
• Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy

  2019cites this paper
• Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations

  2019cites this paper
• Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

  2018cites this paper
• Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer

  2018cites this paper
• An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation‐positive NSCLC: A Strategic Approach

  2018cites this paper
• Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation.

  2018cites this paper
• Mutations as Predictive Biomarkers for Adenocarcinoma

  2018cites this paper
• A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan

  2017cites this paper
• Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer

  2017cites this paper
• Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cites this paper
• Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

  2017cites this paper
• De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

  2017cites this paper
• Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?

  2017cites this paper
• The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer

  2017cites this paper
• Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.

  2016cites this paper
• Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

  2016cites this paper
• Personalizing Therapy for Acquired Resistance to EGFR Kinase Inhibitors in Advanced NSCLC

  2016cites this paper
• Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma

  2016cites this paper
• Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.

  2016cites this paper
• Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

  2015cites this paper
• Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma.

  2015cites this paper
• Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.

  2015cites this paper
• Current and Future Therapeutics for Patients with Non-small Cell Lung Cancer and Known Activating Mutations in Epidermal Growth Factor Receptor

  2015cites this paper
• Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer

  2014cites this paper
• NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer

  2014cites this paper